Mithun Devraj, MD
Interventional Cardiology · Carson City, NVNPI 1396127205
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,248 of the $14,908 with a category attached, or 62.0%. 24 manufacturers reported payments, led by Medtronic at 36.2% of the total. 2025 is the largest year on record at $5,020, more than ten times the $413 reported in 2019.
Across 253 payments — averaging $58.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Boston Scientific$3K
- Abbott$3K
- Edwards Lifesciences$1K
- Shockwave Medical, Inc$872
- Cardiovascular Systems Inc.$457
- plus $1K from 18 others
What the payments were for
- Grants$1,0007%
- Travel & lodging$4,65931%
- Food & beverage$9,24862%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 68 | $5,391 |
| Boston Scientific | 82 | $3,013 |
| Abbott | 49 | $2,536 |
| Edwards Lifesciences | 10 | $1,322 |
| Shockwave Medical, Inc | 5 | $872 |
| Cardiovascular Systems Inc. | 3 | $457 |
| Abiomed | 3 | $312 |
| E.r. Squibb & Sons, L.L.C. | 7 | $298 |
| Asahi Intecc USA, Inc. | 1 | $118 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $74 |
| Novo Nordisk | 3 | $66 |
| Cook Medical LLC | 4 | $60 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $60 |
| Amgen | 3 | $59 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $47 |
| Novartis | 2 | $40 |
| Philips North America LLC | 1 | $26 |
| Bayer | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Recor Medical Inc | 1 | $22 |
| W. L. Gore & Associates, Inc. | 1 | $22 |
| Pfizer | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$3,957
- OPTIS$1,195
- GENERAL - STENTS$1,000
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$872
- Diamondback Coronary$457
- Edwards SAPIEN 3 Transcatheter Heart Valve$426
- AVVIGO Guidance System$257
- ELIQUIS$181
- Impella$166
- DRAGONFLY OPSTAR$150
- OPTICROSS$150
- Watchman$147
- CROSSBOSS$142
- ASAHI PTCA Guide Wire$118
- GENERAL - THERAPIES$116
- ONYX FRONTIER$104
How this compares
$14,908 in reported general payments places this provider in the 65th percentile of 62 interventional cardiology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 181 | $210,240 |
| JardianceEmpagliflozin | 47 | $64,122 |
| EntrestoSacubitril/Valsartan | 41 | $47,298 |
| XareltoRivaroxaban | 45 | $46,275 |
| Repatha SureclickEvolocumab | 19 | $19,886 |
| FarxigaDapagliflozin Propanediol | 11 | $10,279 |
| Rosuvastatin Calcium | 148 | $2,935 |
| Metoprolol Succinate | 181 | $2,208 |
| Atorvastatin Calcium | 153 | $2,167 |
| Ranolazine ErRanolazine | 17 | $1,571 |
| Valsartan | 46 | $1,069 |
| Amlodipine Besylate | 133 | $950 |
| Flecainide Acetate | 23 | $817 |
| Losartan Potassium | 79 | $816 |
| Candesartan Cilexetil | 15 | $775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $20 | $210,240181 claims |
| NovartisEntresto | $40 | $47,29841 claims |
| Johnson & JohnsonXarelto | $24 | $46,27545 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 62 interventional cardiology providers in Nevada.
Other interventional cardiology in Carson City
- Nathan HoCarson City$19K
- Lahdan RefahiyatCarson City$9K
- Cres MirandaLas Vegas$660K
- Jeffrey LevismanHenderson$226K
- Howard BroderHenderson$168K
- Adrian Mercado-AlamoLas Vegas$118K
- Nayab ZafarLas Vegas$102K
- William ChuLas Vegas$75K
- Karthiek NaralaHenderson$44K
- Neville MistryLas Vegas$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.